GenSight Biologics S.A. announced a private placement of common shares at a price of ?0.025 for the gross proceeds of ?1,546,199.455 on May 7, 2024.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.354 EUR | -1.94% | -8.17% | -23.04% |
03/06 | Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors | CI |
03/06 | Gensight Biologics S.A. Appoints Ivan Tortet as Chief Financial Officer | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.04% | 39.9M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.46% | 22.48B | |
-9.65% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- SIGHT Stock
- News GenSight Biologics S.A.
- GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding